SCHEMBL1893101

SCHEMBL1893101

C=C1c2ccc(OC)c(OC)c2C2CN(Cc3ccccc3)CC12

nearest known ligand 0.44

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
BCHE P06276 7/20 0.43
BACE1 P56817 6/20 0.43
ACHE P22303 6/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
DRD4 P21917 1/20 0.41
SLC6A12 P48065 1/20 0.40
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1893868 0.86 HTR2B (0.46) BCHEBACE1ACHEDRD4DRD2
SCHEMBL1897954 0.78 DRD2 (0.46) BCHEBACE1ACHEMEN1KMT2A
SCHEMBL1891610 0.76 FUCA1 (0.41) ACHEDRD4DRD2DRD3
SCHEMBL1892279 0.76 PNMT (0.43) DRD4DRD2DRD3
SCHEMBL1897072 0.75 DRD2 (0.58) BACE1ACHEDRD4DRD2DRD3
SCHEMBL1897649 0.74 FUCA1 (0.41) DRD2DRD3
Hydrochloric Acid SCHEMBL10828111 0.71 DRD2 (0.49) BCHEBACE1ACHEMEN1KMT2A
SCHEMBL1893879 0.70 LMNA (0.44) BCHEBACE1ACHEDRD2DRD3
SCHEMBL1894391 0.70 DPP4 (0.50) SLC6A12DRD2DRD3
Hydrochloric Acid SCHEMBL10505376 0.70 ADRA1B (0.51) BCHEBACE1ACHEDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096520-B2 Tricyclic ideno-pyrrole derivatives as serotonin receptor modulators ABT HOLDING COMPANY (US) 2015-08-04 US disclosed
US-20140206739-A1 TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS ABT HOLDING COMPANY (US) 2014-07-24 US disclosed
US-8716324-B2 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators ATHERSYS, INC. (US) 2014-05-06 US disclosed
US-20120252859-A1 Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators ATHERSYS, INC. (US) 2012-10-04 US disclosed
US-8232311-B2 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators ATHERSYS, INC. (US) 2012-07-31 US disclosed
US-20110172283-A1 Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators BENNANI YOUSSEF L 2011-07-14 US disclosed
US-7935830-B2 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators ATHERSYS, INC. (US) 2011-05-03 US disclosed
US-20090239925-A1 TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS ATHERSYS, INC. 2009-09-24 US disclosed
US-20060025601-A1 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators ATHERSYS, INC. 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252859-A1 Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators HTR5A, HTR3E, HTR1E BCHE 2158/4885BACE1 3831/4885ACHE 1017/4885
US-20110172283-A1 Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators HTR5A, HTR3E, HTR1E BCHE 2158/4885BACE1 3831/4885ACHE 1017/4885
US-20060025601-A1 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators HTR5A, HTR3E, HTR1E BCHE 2158/4885BACE1 3831/4885ACHE 1017/4885
US-20090239925-A1 TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS HTR5A, HTR3E, HTR1E BCHE 2158/4885BACE1 3831/4885ACHE 1017/4885
US-20140206739-A1 TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS HTR5A, HTR3E, HTR1E BCHE 2158/4885BACE1 3831/4885ACHE 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.